SHANGHAI GlaxoSmithKline Plc (GSK.L) has cut 40 percent of its sales reps in China and axed some units as it eyes a return to growth in 2016, after sales plunged during a bribery scandal that landed it with a record $490 million fine in 2014.
Short interest is a direct consequence of short sales, which are governed by special rules and regulations. Short interest is an important indicator that helps you measure investor sentiment about a particular stock or the market in general.
For those who may have missed it, GlaxoSmithKline reported nearly $9.4 billion in revenue during the third quarter, which excludes negative currency movements, translating into growth of 11% from Q3 2014.
However, despite the narrow indications for which it was approved, GSK heavily marketed Lamictal for the treatment of bipolar disorders both before and during the period it was pending a supplemental new drug application for treatment of bipolar I ...